Efficacy and Safety of Umbralisib and Ublituximab (U2), and U2 Plus Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) By admin / 12/12/2021
The Combination of Umbralisib Plus Ublituximab is Active in Patients with Relapsed or Refractory Marginal Zone Lymphoma (MZL): Results from the Phase 2 Global UNITY-NHL Trial By admin / 12/11/2021
The Selective Bruton’s Tyrosine Kinase (BTK) Inhibitor TG-1701 as Monotherapy and in Combination with Ublituximab and Umbralisib (U2) in Patients with B-cell Malignancies By admin / 12/11/2021
Ublituximab Is Associated With Significant Improvement in the Multiple Sclerosis Functional Composite (MSFC): Results From the Phase 3 ULTIMATE I & II Studies By admin / 10/14/2021
Phase 3 Results of the ULTIMATE I & II Global Studies: Ublituximab Versus Teriflunomide in Relapsing Multiple Sclerosis By admin / 10/14/2021
Integrated Safety Analysis of Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor, in Relapsed/Refractory Lymphoid Malignancies By admin / 09/21/2021
TG-1701, a Selective Bruton Tyrosine Kinase (BTK) Inhibitor, as Monotherapy and in Combination with Ublituximab and Umbralisib (U2) in Patients with Chronic Lymphocytic Leukemia By admin / 09/19/2021
Phase I/II Study of Umbralisib (TGR-1202), Ublituximab (TG-1101), and Pembrolizumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Richter’s Transformation: 5-Year Follow-up By admin / 09/18/2021
Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment-Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 UNITY-CLL Study By admin / 09/18/2021
Phase I/II Study of Umbralisib (TGR-1202), Ublituximab (TG-1101), and Pembrolizumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Richter’s Transformation: 5-Year Follow-up By admin / 09/18/2021
